Podcast appearances and mentions of Gustave Roussy

La dernière édition du congrès annuel de la Société américaine d'oncologie clinique, du 30 mai au 3 juin à Chicago, a été l'occasion d'un état des lieux des avancées scientifiques Contre le cancer, une profusion d'avancées et de nouveaux espoirs de guérison. Ecoutez Benjamin Besse, professeur en oncologie médicale et directeur de la recherche clinique à l'institut Gustave Roussy. Ecoutez L'invité pour tout comprendre avec Yves Calvi du 03 juin 2025.Distribué par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Suivre l'évolution d'un cancer avec une simple prise de sang : c'est le pari révolutionnaire de Gustave Roussy. L'Institut lance une étude inédite pour détecter les risques de rechute grâce à la présence d'ADN tumoral circulant dans le sang. Une avancée majeure dans la personnalisation du suivi post-traitement.Distribué par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Suivre l'évolution d'un cancer avec une simple prise de sang : c'est le pari révolutionnaire de Gustave Roussy. L'Institut lance une étude inédite pour détecter les risques de rechute grâce à la présence d'ADN tumoral circulant dans le sang. Une avancée majeure dans la personnalisation du suivi post-traitement.Distribué par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Suivre l'évolution d'un cancer avec une simple prise de sang : c'est le pari révolutionnaire de Gustave Roussy. L'Institut lance une étude inédite pour détecter les risques de rechute grâce à la présence d'ADN tumoral circulant dans le sang. Une avancée majeure dans la personnalisation du suivi post-traitement.Distribué par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Depuis une trentaine d'années, la recherche contre le cancer doit faire face à une augmentation du nombre de malades chez les adultes de moins de 50 ans. Au-delà des facteurs de risque habituels, des études ont été lancées, notamment par le centre Gustave Roussy de Villejuif (Val-de-Marne) pour tenter d'identifier de potentielles causes sociétales comme l'exposition à la pollution et aux pesticides. En parallèle, de plus en plus de personnalités atteintes de cancer sensibilisent le grand public et appellent à la vigilance. Cet épisode de Code Source est raconté par Nicolas Berrod, reporter au service Futurs du Parisien et spécialiste des questions de santé. Écoutez Code source sur toutes les plates-formes audio : Apple Podcast (iPhone, iPad), Amazon Music, Podcast Addict ou Castbox, Deezer, Spotify.Crédits. Direction de la rédaction : Pierre Chausse - Rédacteur en chef : Jules Lavie - Reporter : Barbara Gouy - Production : Pénélope Gualchierotti et Clémentine Spiler - Réalisation et mixage : Théo Albaric - Musiques : François Clos, Audio Network - Archives : Kyan Khojandi, The Guardian. Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

L'actrice belge Emilie Dequenne est décédée ce dimanche en début de soirée à l'âge de 43 ans des suites d'un cancer rare, ont annoncé sa famille et son agente Danielle Gain à l'AFP. Elle s'est éteinte à l'hôpital Gustave Roussy de Villejuif en banlieue parisienne. Elle avait révélé en octobre 2023 être atteinte d'un corticosurrénalome (cancer du système endocrinien), diagnostiqué deux mois auparavant, et qui la tenait depuis éloignée des plateaux de tournage. Emilie Dequenne était née le 29 août 1981 à Beloeil. Elle est révélée au grand public par son interprétation dans le drame "Rosetta" des frères Dardenne qui lui vaut le prix d'interprétation féminine en 1999 au festival de Cannes. Merci pour votre écoute N'hésistez pas à vous abonner également aux podcasts des séquences phares de Matin Première: L'Invité Politique : https://audmns.com/LNCogwPL'édito politique « Les Coulisses du Pouvoir » : https://audmns.com/vXWPcqxL'humour de Matin Première : https://audmns.com/tbdbwoQRetrouvez tous les contenus de la RTBF sur notre plateforme Auvio.be Retrouvez également notre offre info ci-dessous : Le Monde en Direct : https://audmns.com/TkxEWMELes Clés : https://audmns.com/DvbCVrHLe Tournant : https://audmns.com/moqIRoC5 Minutes pour Comprendre : https://audmns.com/dHiHssrEt si vous avez apprécié ce podcast, n'hésitez pas à nous donner des étoiles ou des commentaires, cela nous aide à le faire connaître plus largement. Distribué par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Dr. Wilfried Ellmeier is a Co-Chair of the Scientific Planning Committee at the International Union of Immunological Societies (IUIS) and Professor of Immunobiology and Head of the Institute of Immunology at the Medical University of Vienna. Dr. Laurence Zitvogel is a Keynote Speaker at IUIS 2025 and a Professor and Group Leader at Gustave Roussy. Dr. Dan Littman is also a Keynote Speaker at IUIS 2025 and Professor of Cell Biology and Helen L. and Martin S. Kimmel Professor of Molecular Immunology at NYU Langone. This episode features a discussion on  the upcoming IUIS 2025 Congress taking place August 17-22 in Vienna, Austria. They talk about what to expect at the meeting, highlights from this year's program, and where to explore in Vienna.

durée : 00:09:45 - L'invité de 7h50 - par : Sonia Devillers - Suzette Delaloge, oncologue médicale spécialiste du cancer du sein à Gustave-Roussy et directrice du programme de prévention personnalisée Interception, était l'invitée du 7h50 de France Inter ce mardi, à l'occasion de la Journée mondiale contre le cancer. - invités : Suzette Delaloge, - Suzette Delaloge : Oncologue, responsable du comité de pathologie mammaire de Gustave Roussy

durée : 00:09:45 - L'invité de 7h50 - par : Sonia Devillers - Suzette Delaloge, oncologue médicale spécialiste du cancer du sein à Gustave-Roussy et directrice du programme de prévention personnalisée Interception, était l'invitée du 7h50 de France Inter ce mardi, à l'occasion de la Journée mondiale contre le cancer. - invités : Suzette Delaloge, - Suzette Delaloge : Oncologue, responsable du comité de pathologie mammaire de Gustave Roussy

En cette journée consacrée à la lutte contre le cancer, Fabrice Barlesi revient sur les avancées technologiques récentes, permettant un traitement de plus en plus adapté à chaque patient. Mention légales : Vos données de connexion, dont votre adresse IP, sont traités par Radio Classique, responsable de traitement, sur la base de son intérêt légitime, par l'intermédiaire de son sous-traitant Ausha, à des fins de réalisation de statistiques agréées et de lutte contre la fraude. Ces données sont supprimées en temps réel pour la finalité statistique et sous cinq mois à compter de la collecte à des fins de lutte contre la fraude. Pour plus d'informations sur les traitements réalisés par Radio Classique et exercer vos droits, consultez notre Politique de confidentialité.Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Plus de 80% d'augmentation du cancer chez les jeunes en 20 ans : "il faut se préparer à un Tsunami", alerte le Professeur Fabrice Barlesi, directeur général de l'Institut Gustave Roussy, premier centre de lutte contre le cancer en Europe. Ecoutez L'invité d'Amandine Bégot du 03 février 2025.

Le cancer frappe des patients de plus en plus jeunes : le nombre de malades âgé de 20 à 40 ans a presque doublé en 30 ans. Pour l'institut Gustave Roussy, on s'apprête à faire face à un "tsunami" de malades du cancers chez des jeunes adultes. Les scientifiques multiplient les projets de recherche pour comprendre pourquoi, mais la maladie frappe de plus en plus de jeunes. Agathe Landais a rencontré pour RTL un jeune patient atteint d'un cancer. Ecoutez RTL inside avec Agathe Landais du 03 février 2025.

REDIFF - Un matin, à l'institut Gustave Roussy de Villejuif, la docteure Mansouriah Merad reçoit une femme de cinquante ans. Depuis deux jours, cette patiente atteinte d'un cancer du sein pousse des cris de douleur. Étonnamment, les examens sont satisfaisants et aucun problème apparent ne permet d'expliquer ses souffrances actuelles. Au départ, la médecin pense qu'il s'agit d'une détresse psychologique. Pour cause, cette mère de deux enfants affronte une récidive agressive de son cancer, ce qui pourrait expliquer l'apparition de troubles du comportement. Pourtant, son état clinique se dégrade et les questions tourbillonnent dans la tête du docteure Merad...

REDIFF - Un matin, à l'institut Gustave Roussy de Villejuif, la docteure Mansouriah Merad reçoit une femme de cinquante ans. Depuis deux jours, cette patiente atteinte d'un cancer du sein pousse des cris de douleur. Étonnamment, les examens sont satisfaisants et aucun problème apparent ne permet d'expliquer ses souffrances actuelles. Au départ, la médecin pense qu'il s'agit d'une détresse psychologique. Pour cause, cette mère de deux enfants affronte une récidive agressive de son cancer, ce qui pourrait expliquer l'apparition de troubles du comportement. Pourtant, son état clinique se dégrade et les questions tourbillonnent dans la tête du docteure Merad...

Os casos de câncer entre os jovens de 20 a 40 anos vêm crescendo de maneira contínua nos últimos 30 anos, segundo dados apresentados pelo Instituto francês Gustave Roussy, que busca ampliar sua atuação em pesquisa, prevenção e tratamento. O estabelecimento público, situado em Villejuif, nos arredores de Paris, é um dos maiores centros de luta de combate ao câncer do mundo e considerado uma referência em testes de novos medicamentos e terapias.  Taíssa Stivanin, da RFI em ParisOs cânceres do intestino, pâncreas e rins, por exemplo, se tornaram mais comuns nesta faixa etária, o que representa "um verdadeiro desafio para os cientistas", explicou à RFI o oncologista Fabrice Barlesi, diretor-geral do Instituto Gustave Roussy.“Não entendemos exatamente o porquê deste aumento, mas há pistas. Alguns estudos mostram que pode haver uma relação entre o consumo de ultraprocessados e o câncer. Mas isso não significa que haja necessariamente uma causalidade, ou seja, uma relação de causa e efeito.”O aumento impressiona os cientistas, afirma, e as perspectivas exigem ação imediata. Uma pesquisa internacional recente divulgada na revista científica British Medical Journal revelou que, entre 1990 e 2019, houve um aumento de 79,1% de certos tipos de câncer em pessoas com menos de 50 anos, em todo o mundo. As conclusões de outro estudo, divulgado em dezembro de 2024 pela revista Lancet Oncology, prevêem uma alta de 12% de novos diagnósticos e mortes causadas pela doença nesta faixa etária, entre 2022 e 2050.O fato é que a curva estatística que traduz o aumento dos casos entre jovens não se estabiliza ou registra queda nas últimas três décadas. Na prática, isso indica que, independentemente do método utilizado para analisar os dados, a alta dos cânceres nessa população parece ser uma realidade incontestável, explicou Fabrice André, diretor de pesquisa do instituto francês.De acordo com ele, ainda serão necessários muitos estudos para confirmar cientificamente as hipóteses que explicariam o aumento do número de casos. "Isso pode levar vários anos”, observa. Confirmar as hipóteses ambientais que estariam por trás do adoecimento dos jovens adultos também é fundamental para adotar medidas de prevenção e evitar a alta de certos tipos de cânceres nas próximas gerações.Com provas científicas, os Estados, com o tempo, seriam assim obrigados a adotar legislações mais protetoras. Foi o que aconteceu com o cigarro, um agente cancerígeno que, há 25 anos, era consumido sem moderação no espaço público. Apesar do lobby da indústria do tabaco, os governos com o passar das décadas não tiveram outra escolha, a não ser agir.“Hoje nós não podemos dizer que conhecemos, de maneira científica, as causas dos cânceres nos mais jovens. Por isso é importante lançar estudos e coortes (NR: grupos de pacientes), para termos mais dados precisos e demonstrar, de maneira científica, com provas, qual é a causa desse aumento”, acrescenta Fabrice André. “Mas o fato é que tenho medo pelos meus filhos quando eles terão 30 anos”, alerta.  A frase, que chamou a atenção dos jornalistas presentes na coletiva de imprensa organizada pelo instituto na capital francesa, é mais um "choque de realidade" do que necessariamente alarmista, explicou o oncologista.“Há duas causas possíveis para a explosão desses cânceres. Uma delas é a exposição mais precoce a fatores de risco para a doença. Por exemplo, acreditamos que a inflamação crônica pode favorecê-la. Desta forma, estar exposto de maneira mais precoce a uma inflamação poderia provocar um câncer”, diz.  “A segunda causa seria a exposição a novos fatores de risco. Neste caso, uma das hipóteses é o consumo de alimentos ultraprocessados, ou a exposição do jovem durante sua vida a agentes cancerígenos, por exemplo”, explica.“Outra hipótese é a obesidade. As transformações metabólicas e a inflamação que ela provoca podem estar associadas ao câncer. Mas não temos provas científicas”, reitera. “O papel da poluição e dos microplásticos também deve ser estudado, mas, mais uma vez são apenas hipóteses. Lançar hipóteses é fácil, o mais complicado é validá-las.  Por isso temos que definir essas causas e realizar estudos que nos permitirão coletar dados e amostras celulares", resume.Outra preocupação, lembra, é o crescimento do número de casos de certos cânceres raros, como do intestino delgado, que estão aparecendo com mais frequência nesta faixa etária. E, mais uma vez, não há por enquanto nenhuma explicação científica para esse fenômeno, que intriga os pesquisadores.Investimento em pesquisaPara validar hipóteses, são necessárias pesquisas com grandes grupos de pacientes de diferentes faixas etárias. Na França, estudos epidemiológicos sobre o aumento de certos tipos de câncer em jovens, por exemplo, já estão em andamento. Eles permitirão coletar dados detalhados sobre o modo de vida dos pacientes durante a infância. O objetivo é elencar fatores ambientais que estariam envolvidos no desenvolvimento da doença, utilizando recursos estatísticos e algorítmicos sofisticados.Na segunda etapa, os cientistas deverão analisar especificamente os dados de grupos de pacientes que desenvolveram cânceres mais jovens. A meta é caracterizá-los e compará-los aos cânceres dos pacientes mais velhos para, em seguida, constatar em laboratório eventuais diferenças moleculares e celulares. “Precisamos entender como esses cânceres aparecem. Será que existem especificidades relacionadas aos órgãos onde eles surgem? Será que decorre do envelhecimento do tubo digestivo, que tem características próprias? Existe um fator sistêmico, ligado a nosso sistema de defesa contra a doença? Ou será que existem outros aspectos que desconhecemos e, se for o caso, de que maneira podemos tratá-los?", questiona o diretor-geral do instituto, Fabrice Barlesi. Neste contexto, o centro francês busca reforçar sua estratégia de prevenção personalizada, diagnóstico precoce e Medicina de precisão. O objetivo é proporcionar aos pacientes o melhor prognóstico possível, com qualidade de vida. “Esse é um dos desafios. Se um paciente de 40 anos tem um câncer e é curado, terá ainda muitos anos pela frente. Esses anos devem ser bem vividos”, frisa o oncologista. Novos projetosO Instituto Gustave Roussy também será ampliado para facilitar os tratamentos e estudos clínicos. Para isso, estão previstos investimentos de € 53 milhões. Três projetos ilustram as metas nos próximos anos. O primeiro, Yoda (Young Onset Digestive Adenocarcinoma), busca identificar os fatores envolvidos no aparecimento de cânceres digestivos em pacientes com menos de 50 anos e propor um plano de prevenção. No primeiro semestre deste ano, dois grupos de pacientes entre 20 e 49 anos e 65 e 70 anos serão selecionados para participar do estudo. O segundo projeto visa desenvolver um teste diagnóstico para detectar a doença em mulheres jovens que apresentam um envelhecimento acelerado das células mamárias e correm mais risco de desenvolver um tipo agressivo de câncer de mama.A terceira iniciativa visa otimizar a rapidez do diagnóstico e a proposta de tratamento. O dispositivo, conhecido como InstaDiag, já é aplicado há anos em mulheres com câncer de mama e agora beneficia outras patologias.  Há, ainda, outras iniciativas paralelas. “Temos também um programa chamado Interception, cujo objetivo é identificar, o mais precocemente possível, se o paciente tem um risco maior, que pode estar relacionado a seu histórico familiar ou a anomalias genéticas. Esse programa visa toda a população francesa”, completa o oncologista. Outra ambição é dentro de alguns anos generalizar a biópsia líquida, menos invasiva, e que pode ser coletada com um simples exame de sangue, para monitorar metástases.Há também a proposta de disponibilizar aos pacientes testes sanguíneos que detectam cânceres, assintomáticos, em estágios ultraprecoces, que normalmente não são alvos de campanhas de prevenção. Testes parecidos, que analisam o DNA do paciente, já estão disponíveis nos EUA, mas há controvérsias sobre sua eficácia.Enquanto a Ciência avança para propor cada vez mais terapias e tratamentos que visam a cura, o diretor-geral do Instituto Gustave Roussy lembra que nunca é tarde para adotar algumas mudanças no estilo de vida que previnem a doença: 40% dos cânceres em geral podem ser evitados e estão associados ao tabagismo, consumo de álcool, sedentarismo e sobrepeso. 

Anwar Dahab, directeur général de Dell Technologies France, et Marc Deloger, responsable de la plateforme bioinformatique de Gustave Roussy, étaient les invités de François Sorel dans Tech & Co, la quotidienne, ce mardi 5 novembre. Ils se sont penchés sur le partenariat entre Dell et Gustave Roussy et sur le jumeau numérique pour la médecine de précision, sur BFM Business. Retrouvez l'émission du lundi au jeudi et réécoutez la en podcast.

Mardi 5 novembre, François Sorel a reçu Frédéric Simottel, journaliste BFM Business, Yves Maitre, operating partner Jolt capital et consultant, ancien PDG de HTC, Philippe Dewost, fondateur de Phileos, ancien directeur général de l'EPITA, cofondateur de Wanadoo, Michel Levy Provençal, prospectiviste, fondateur de TEDxParis et de l'agence Brightness, Léa Benaim, journaliste BFM Business, Anwar Dahab, directeur général de Dell Technologies France, Marc Deloger, responsable de la plateforme bioinformatique de Gustave Roussy, Salomé Ferraris, journaliste Tech&Co, Charles Christory, cofondateur Le Fourgon, Max Herrmann, cofondateur de Nopli, et Antoine Rostand, président et cofondateur de Kayrros, dans l'émission Tech & Co, la quotidienne sur BFM Business. Retrouvez l'émission du lundi au jeudi et réécoutez la en podcast.

A radioterapia para tratar tumores do seio que já atingiram os gânglios linfáticos agora terá três semanas em vez de cinco, segundo um estudo dirigido pela oncologista e radioterapeuta Sofia Rivera, do instituto francês Gustave Roussy. Os resultados foram divulgados em setembro, durante o congresso da ESMO, a Sociedade Europeia de Oncologia, que todos os anos apresenta os últimos avanços na luta contra a doença.  Taíssa Stivanin, da RFI em ParisA pesquisa mostrou que a eficácia da radioterapia de 15 sessões em três semanas, com doses um pouco mais fortes de radiações, é similar a 25 sessões de cinco semanas.A descoberta foi anunciada após a fase 3 do estudo, chamado de HypoG-01. Os resultados apresentados modificarão o protocolo de tratamento radioterápico aplicado em pacientes do mundo todo, segundo a oncologista francesa.Os testes clínicos aconteceram em 29 estabelecimentos franceses, entre setembro de 2016 e março de 2020. A idade média das 1 265 pacientes era 58 anos e todas haviam sido operadas de um câncer do seio locorregional, ou seja, que atingiram os gânglios. O estudo vai facilitar a vida das pacientes, explicou a oncologista e radioterapeuta Sofia Rivera. “O HypoG-01, apresentado em uma sessão da Sociedade Europeia de Oncologia Médica, é o primeiro estudo a demonstrar que quando tratamos um câncer com um volume maior, podemos fazer uma radioterapia mais curta e passar de cinco para três semanas de tratamento”, explicou à RFI.A radioterapia é a última etapa do tratamento contra o câncer de mama. Duas semanas a menos é um verdadeiro “alívio” para as pacientes, mas também para o já sobrecarregado sistema de saúde francês, que tem cada vez mais dificuldade em atender a demanda.“Esse tempo mais curto também representa uma redução de custos e menos idas e vindas das pacientes aos hospitais” diz a oncologista. A redução do tempo da radioterapia também libera vagas nas máquinas para atender outras mulheres mais rapidamente e aumenta em alguns casos as chances de sobrevida e de cura.Na França, cerca de 90% dos cânceres de mama são descobertos no estágio inicial ou já atingiram os gânglios, sem metástases em outros órgãos.Efeitos colateraisPara ser validado e garantir a segurança das pacientes, o estudo se concentrou nos eventuais efeitos colaterais que poderiam surgir por conta da maior intensidade das radiações. “Quando irradiamos os gânglios, irradiamos também mais tecidos normais. Temos o coração, e atrás dos gânglios, embaixo da clavícula, o pulmão, além dos vasos e nervos dos braços", descreve Sofia Rivera."Um dos temores era que as pacientes tivessem mais efeitos colaterais e linfedemas, ou seja, braços inchados. É um risco que aparece após a cirurgia e a radioterapia dos gânglios. Mas o estudo mostrou que as pacientes não tinham mais reações adversas. Pelo contrário, tinham até menos, porque sentiam menos cansaço. Nossa conclusão é que só há benefícios para elas”, resume.Além do tratamento em si, não é apenas o caminho de casa até o hospital que cansa as pacientes. Há também a adaptação aos horários das consultas e a expectativa na sala de espera, muitas vezes ao lado de outras mulheres tratadas por cânceres mais graves. “Isso pode ser psicologicamente difícil”, destaca a oncologista.Vantagem em zonas de guerraDesde a apresentação do estudo no congresso europeu, vários centros de tratamento adotaram o novo protocolo e a oncologista francesa foi procurada por profissionais de vários países, inclusive da Ucrânia."Felizmente as radioterapias continuaram no país apesar da guerra e diminuir os deslocamentos das pacientes é um benefício incontestável", lembra. “Vamos organizar um workshop online para ajudar as equipes e formá-las para adotar esse novo tratamento”.Ela lembra que o diagnóstico precoce continua sendo um dos maiores aliados das pacientes e, neste caso, as chances de cura podem chegar a 100%, lembra Sofia Rivera. Ela lamenta que na França muitas mulheres simplesmente não façam a mamografia periodicamente, apesar de o exame ser gratuito no país.“Ainda temos taxas de mamografia de rotina muito baixas. Hoje na França, menos de 50% das mulheres que deveriam realizar a mamografia de rotina fazem o exame”. É importante também, diz, implantar estratégias para promover e possibilitar exames de rotina personalizados, em função do risco da paciente.  A recomendação para filhas de mulheres que tiveram câncer do seio é começar o exame de rotina cinco antes do diagnóstico da mãe e realizar uma mamografia anualmente, ou a cada dois anos. Essa precaução deve ser acompanhada, além do autoexame, de uma visita ao ginecologista ou clínico geral, já que os nódulos podem ser detectados em um exame clínico.

Retrouvez dans cet épisode le passionnant récit de la Saga de l'association Princesse Margot, fondée par Muriel Attab. Depuis plus de 12 ans, cette association œuvre pour améliorer le quotidien des enfants et adolescents atteints de cancer hospitalisés.Vous découvrirez comment Princesse Margot a réussi à apporter de la joie et du réconfort à ces jeunes patients grâce à des initiatives innovantes, comme les « Repas Toqués ». Chaque mercredi, des chefs étoilés viennent cuisiner de délicieux repas pour les enfants soignés à l'hôpital Gustave Roussy, redonnant ainsi le sourire et l'appétit à ces petits malades.Mais Princesse Margot ne s'arrête pas là. Pendant la période du COVID-19, l'association a également créé des sacs-surprises remplis de gourmandises et de petits cadeaux pour égayer le quotidien des jeunes patients. Car au-delà de l'alimentation, c'est tout un univers de douceur et de réconfort que Muriel Attab et son équipe s'efforcent de transmettre à ces enfants et leurs familles confrontés à la maladie.Plongez dans cette formidable saga d'une association qui, à travers la gastronomie, apporte un rayon de soleil dans la vie des plus fragiles. Un épisode inspirant qui montre tout le bien que peut faire la solidarité et la créativité lorsqu'elles s'unissent pour une noble cause.Notre équipe a utilisé un outil d'Intelligence artificielle via les technologies d'Audiomeans© pour accompagner la création de ce contenu écrit.

Retrouvez dans cet épisode le passionnant récit de la Saga de l'association Princesse Margot, fondée par Muriel Attab. Depuis plus de 12 ans, cette association œuvre pour améliorer le quotidien des enfants et adolescents atteints de cancer hospitalisés.Vous découvrirez comment Princesse Margot a réussi à apporter de la joie et du réconfort à ces jeunes patients grâce à des initiatives innovantes, comme les « Repas Toqués ». Chaque mercredi, des chefs étoilés viennent cuisiner de délicieux repas pour les enfants soignés à l'hôpital Gustave Roussy, redonnant ainsi le sourire et l'appétit à ces petits malades.Mais Princesse Margot ne s'arrête pas là. Pendant la période du COVID-19, l'association a également créé des sacs-surprises remplis de gourmandises et de petits cadeaux pour égayer le quotidien des jeunes patients. Car au-delà de l'alimentation, c'est tout un univers de douceur et de réconfort que Muriel Attab et son équipe s'efforcent de transmettre à ces enfants et leurs familles confrontés à la maladie.Plongez dans cette formidable saga d'une association qui, à travers la gastronomie, apporte un rayon de soleil dans la vie des plus fragiles. Un épisode inspirant qui montre tout le bien que peut faire la solidarité et la créativité lorsqu'elles s'unissent pour une noble cause.Notre équipe a utilisé un outil d'Intelligence artificielle via les technologies d'Audiomeans© pour accompagner la création de ce contenu écrit.

durée : 00:09:33 - Les Nuits de France Culture - par : Albane Penaranda - Le résistant Pierre Brossolette se suicide par défenestration le 22 mars 1944 pour ne pas parler sous la torture. Un an après une cérémonie à sa mémoire est organisée à Paris, à la Sorbonne. Avec les discours de Gustave Roussy, Maurice Schumann, Waldeck Rochet et René Pleven parmi d'autres.

A cientista francesa Elsa Bernard é chefe da equipe de oncologia computacional do instituto francês Gustave Roussy, um dos maiores centros de combate ao câncer no mundo, situado em Villejuif, nos arredores de Paris. Ela é uma das autoras de um estudo recente, publicado na revista científica Cell, que busca entender os mecanismos individuais e ambientais que estão na origem do aparecimento de diferentes tipos de cânceres. Taíssa Stivanin, da RFIDesde o início de sua carreira, a pesquisadora francesa focou seus estudos na análise de dados moleculares, uma das áreas da Biologia Matemática aplicada à Cancerologia. Após uma temporada nos Estados Unidos e no Reino Unido, onde concluiu seu pós-doutorado, ela voltou para Paris e desde setembro de 2023 integra a equipe do instituto francês Gustave Roussy. O trabalho realizado pela cientista permite acompanhar em detalhes as mutações celulares individuais antes mesmo do aparecimento da doença.“O câncer atinge todo mundo e os estudos em Oncologia estão em plena transformação. Os dados, principalmente moleculares, são cada vez mais importantes para entender e tratar clinicamente a doença. Eles são gerados cada vez mais e de forma sistemática", explicou a cientista à RFI. "Estamos na era da Medicina de precisão. Podemos utilizar esses dados e explorá-los o máximo possível para prever e entender a evolução da doença em certos casos”, acrescenta.O estudo publicado na revista científica Cell reúne o trabalho de pesquisadores de diversos países, que identificaram fatores biológicos que podem influenciar no desenvolvimento de um tumor. Essa lista é chamada pelos cientistas de clouds de complexité (nuvens de complexidade, em tradução livre), que são os diferentes parâmetros de interação entre um paciente e seu câncer.Entre eles, está análise do papel das células que sofreram mutações antes e depois de se transformarem em tumores, além das razões individuais e ambientais que levam ao surgimento do câncer. Elsa Bernard lembra que nem todas as células que mutam serão cancerígenas e entender por que isso acontece é primordial para prevenir e tratar a doença.“Já sabemos há cerca de 50 anos quais são os gatilhos de transformação de uma célula em cancerígena. Isso ocorre, geralmente, a partir de uma instabilidade no genoma e da sua capacidade de escape imunológico. Esse conjunto de processos é indispensável para essa transformação. Mas ainda sabemos pouco sobre a relação entre o indivíduo e seu tumor”, observa.A evolução da doença ainda depende de outros fatores mais complexos. Entre eles, a interação com células em torno do tumor e outros órgãos, que permitirá aos cientistas entender melhor como os cânceres se manifestam e desta forma preveni-los e até mesmo curá-los, explica a pesquisadora francesa.Entendendo as mutaçõesMas o aparecimento da doença ainda possa ser, em muitos casos, aleatório. “Apesar do câncer ser uma doença genética, relacionada, na maior parte dos casos, à uma mutação do DNA, sabemos que essas mutações hoje não são suficientes para desencadear a doença. "Existem células normais, que nunca se tornarão cancerígenas, e que têm mutações no DNA. "Também há outros elementos, ambientais ou próprios ao indivíduo, que fazem com que a célula que sofreu essa mutação se torne cancerígena."A cientista francesa cita como exemplo infecções virais ou uma inflamação, que podem ter repercussões celulares que levem ao aparecimento do câncer. O tabagismo, o consumo de álcool e o sedentarismo são alguns dos fatores de risco ambientais conhecidos e alvo de recomendações oficiais.Estudos também apontam que a poluição tem um papel preponderante no desenvolvimento de um câncer. O ritmo circadiano, o relógio biológico que coordena as funções fisiológicas quando dormimos ou estamos acordados, também atua na comunicação entre as células, inclusive cancerígenas."No futuro, será essencial para a prevenção saber quais são os fatores de risco individuais, ligados ao seu DNA e à sua história pessoal e familiar, e aqueles associados ao meio ambiente e outros fatores externos”, conclui a pesquisadora.

Cet épisode est publié dans le cadre du Podcashton, il soutient l'institut Gustave Roussy qui fait de la recherche pour les cancers gynécologiques. Notre invitée, Élise, a choisi cette cause car c'est un cancer des ovaires très rare qui a emporté sa petite soeur très jeune et très rapidement. Élise raconte comment se sont passées chaque étape du cancer : le diagnostique, les multiples chimiothérapie, les interventions chirurgicales lourdes jusqu'à la décision d'arrêter les traitements. Ce récit est bouleversant mais il met surtout en lumière la force de Louise, la petite soeur d'Élise, et la résilience de cette famille. On aborde également les sujets des relations extra-familiales (amoureuses notamment) et de l'impact de la maladie dans toutes les sphères de la vie, mais aussi comment vivre avec la culpabilité du survivant et comment faire son deuil tout en honorant une promesse. Pour Élise, sa bulle d'oxygène c'est ce roman, La vie en turquoise, qu'elle a écrit pour raconter toute cette histoire et qui est paru aux éditions Lézard des mots. N'oubliez pas de vous rendre sur le site du Podcasthon pour faire un don à l'institut Gustave Roussy et pour voir toutes les autres associations soutenues par les autres podcasts.Ressources :Suivre Élise sur Instagram : https://www.instagram.com/gd_elise/La vie en turquoise, Lézards des mots : https://lezarddesmots.fr/la-vie-en-turquoise/Le site du Podcasthon : https://www.podcasthon.org/Le site de l'institut Gustave Roussy : https://www.gustaveroussy.fr/Pour nous raconter votre histoire ou nous proposer un sujet, envoyez-nous un mail à 100tabou.podcast@gmail.com, ce sera un plaisir d'en discuter avec vous !Si vous voulez nous aider à libérer les paroles et engager de nouvelles conversations, partagez le podcast autour de vous, que ce soit sur vos réseaux sociaux ou à vos proches.Tous les épisodes sont disponibles également sur le blog : https://100tabou-podcast.com/Crédit musique : S-Coast https://soundcloud.com/s-coastCe podcast est produit par Positiv StudioSite internet : https://www.positivstudio.com/Instagram : https://www.instagram.com/ps.podcastmanager/LinkedIn : https://www.linkedin.com/company/positiv-studio/À très vite ! Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

Ils sont quelques milliers dans le monde à avoir survécu à un cancer réputé incurable: CURE 51 va analyser les caractéristiques de ces patients "exceptionnels" pour tenter de répliquer à grande échelle les mécanismes qui leur ont permis de déjouer tous les pronostics.En anglais, on les appelle les "outliers": "il s'agit de personnes qui vont prendre face à la maladie, pour des raisons inconnues, une trajectoire totalement différente de celle des autres", explique à l'AFP Nicolas Wolikow.Ce spécialiste du monde de la santé est l'un des deux entrepreneurs à l'origine du lancement il y a trois ans de Cure 51, une jeune pousse cofondée par des centres d'oncologie mondialement reconnus comme Gustave-Roussy ou Léon-Bérard en France, l'institut d'oncologie de Milan, ou l'hôpital de la Charité à Berlin.Ils s'apprêtent aujourd'hui à constituer "la première base de données mondiale de survivants du cancer".Become a supporter of this podcast: https://www.spreaker.com/podcast/frenchweb-business--3299227/support.

Le prestigieux centre de lutte contre le cancer Gustave Roussy dans le Val-de-Marne a dessiné en conférence de presse les contours de ce que seront les traitements du cancer de demain. Ecoutez Ca va beaucoup mieux avec Jimmy Mohamed du 25 janvier 2024 avec Jimmy Mohamed.

The therapeutic landscape of advanced urothelial cancer has undergone a significant transformation in recent years with the addition of PD-1/PD-L1 targeting immune checkpoint inhibitors and novel antibody-drug conjugates to the treatment armamentarium. In this Clinical Insights on the Treatment Algorithm in Unresectable Locally Advanced or Metastatic Urothelial Cancer, experts in the field will discuss the latest evidence supporting the use of these therapies in clinical practice, including patient selection for cisplatin/carboplatin eligible and platinum ineligible and optimal treatment strategy in the first-line setting, sequencing of treatments and the management of treatment-related adverse events. An improved understanding of the role and application of immunotherapy, chemotherapy, antibody-drug conjugates (ADC) and targeted treatments to routine patient care will facilitate optimal management of patients with urothelial cancer.During this Expert Interview, we will be discussing the second-line treatment decision-making: How to identify the sequential treatment strategy?  We are joined today by a leading expert in urothelial cancer, Dr Yohann Loriot from the Université Paris-Saclay and Gustave Roussy, Villejuif, France. 

Je reçois Alain Gaffinel, thérapeute à Paris et médecin réanimateur à l'hôpital Gustave Roussy, pour explorer sa compréhension de l'haptonomie, de l'hypnose et de la psychothérapie.Le site d'Alain : https://www.alaingaffinel.com/Mon site : https://www.fabricemidal.comMots clé :Médecin Réanimateur à l'hôpital depuis plus de 20 ans, j'ai décidé de m'installer en ville à temps partiel pour proposer des consultations individuelles à des adultes qui « souffrent ».Cette souffrance peut être intense ou non, précise ou vague, récente ou ancienne.L'originalité et le point commun des approches que je propose - hypnose, haptonomie et méditation - est qu'elles s'intéressent à la partie saine de la personne et qu'elles s'appuient sur leurs propres capacités vitales. Il s'agit de nourrir ou de renourrir la partie saine, de recontacter ou réorienter les capacités vitales de la personne pour qu'elle aille mieux.MON ENGAGEMENT À L'HÔPITALTravaillant dans un hôpital réputé de cancérologie, je suis engagé de manière quotidienne auprès de patients et de leurs familles en souffrance. Ce métier passionnant et intense m'a exposé à beaucoup de souffrances, d'émotions, d'inquiétudes et j'ai pu mesurer les fragilités comme les forces des êtres-humains. Les personnes malades, leurs proches, les soignants réunis dans le même endroit forment un monde à l'image de celui dans lequel nous vivons au quotidien.Pour survivre dans ce monde il faut certaines choses. Souvent nous y avons accès.Pour vivre il en faut d'autres. Nous ne savons pas toujours quoi et, lorsque nous pressentons ce « quoi », nous ne savons pas toujours par où aller chercher.LA RENCONTRE AVEC LA MÉDITATIONA la recherche de ce « quoi et du comment » j'ai d'abord rencontré la méditation dans les années 1990. A cette époque-là c'était pour polir mon esprit en parallèle avec la pratique d'arts martiaux japonais. Quelques années plus tard c'était pour toucher « l'esprit vide » dans la tradition du Tchan transmise par un enseignant de Qi Gong. Enfin à partir de 2002 ce fut la rencontre avec Fabrice Midal et le début d'un merveilleux chemin où la méditation est devenue un moment de rencontre avec moi-même et le monde, un chemin poétique et humain.On peut entendre la méditation comme une manière de se calmer et de s'améliorer. Je considère plutôt que nous passons tous énormément de temps à nous corriger, à nous adapter et à nous améliorer et que finalement il faudrait vraiment être fou pour en plus s'asseoir en silence sur un coussin pour encore s'améliorer.La méditation telle que je l'entends, et telle que je suis parfois amené à la proposer à un patient, est un moment de retrait paisible où l'on s'accueille aussi gentiment que l'on ferait avec un ami tendre. Un moment sans durée et sans objectif précis où on s'assoit au cœur du flux de la vie. A cette pratique sans forme on peut associer des pratiques d'autocompassion et de bienveillance qui sont comme des douches apaisantes et bienfaisantes. Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

BUFFALO, NY- January 10, 2024 – A new #editorial paper was #published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 15, Issue 24, entitled, “Exploring clonal hematopoiesis and its impact on aging, cancer, and patient care.” In this new editorial, researchers Julieta Elena Rodriguez, Jean Baptiste Micol and Capucine Baldini from Gustave Roussy discuss clonal hematopoiesis. Clonal hematopoiesis (CH) is a term that refers to the presence in blood cells of hematologic malignancy-associated somatic mutations without fulfilling the diagnostic criteria of hematologic disease. Emerging evidence suggests that CH is a consequence of an expansion of cells harboring initiating driver mutations, potentially linked to the aging hematopoietic system. While these detectable somatic mutations are rare in individuals under 40 years old, they become increasingly prevalent in the elderly population, a term called age-related clonal hematopoiesis (ARCH), reaching up to 18.4% in those aged 90 years or older. Aging itself is a significant stressor associated with CH, particularly in individuals over 70 years old. DNMT3A, TET2, and ASXL1 mutations are more common with advancing age. “Recent evidence also indicates that CH may play a role in solid tumors, such as an increased risk of incident lung cancer [4]. While initial studies associated CH mutations with worse survival outcomes [5], newer findings suggest that solid tumor patients with CH may experience longer survival [6]. However, the underlying mechanisms behind this relationship remain to be elucidated.” DOI - https://doi.org/10.18632/aging.205404 Corresponding author - Capucine Baldini - capucine.baldini@gustaveroussy.fr Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.205404 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, clonal hematopoiesis, solid tumors About Aging-US Launched in 2009, Aging-US publishes papers of general interest and biological significance in all fields of aging research and age-related diseases, including cancer—and now, with a special focus on COVID-19 vulnerability as an age-dependent syndrome. Topics in Aging-US go beyond traditional gerontology, including, but not limited to, cellular and molecular biology, human age-related diseases, pathology in model organisms, signal transduction pathways (e.g., p53, sirtuins, and PI-3K/AKT/mTOR, among others), and approaches to modulating these signaling pathways. Please visit our website at https://www.Aging-US.com​​ and connect with us: SoundCloud - https://soundcloud.com/Aging-Us Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Media Contact 18009220957 MEDIA@IMPACTJOURNALS.COM

O ano de 2023 foi marcado pelo fim da pandemia de Covid-19. O SARS-CoV-2 não desapareceu e ainda provoca picos de contaminações, mas a vida voltou ao normal após três anos de restrições e graças ao desenvolvimento de vacinas que evitam formas graves e mortes pela Covid-19. A tecnologia do RNA mensageiro, usada nos imunizantes da Pfizer e da Moderna, que permitiram o controle da doença, recebeu o prêmio Nobel de Medicina em 2023. A cientista húngara Katalin Karikó, de 68 anos dividiu a recompensa com o pesquisador americano Drew Weissman.Karikó descobriu, em 2005, como impedir o sistema imunológico de desencadear uma reação inflamatória contra o RNA mensageiro fabricado em laboratório. As pesquisas da bioquímica foram a base do desenvolvimento das vacinas contra a Covid-19, que permitiram o controle epidêmico.Trabalho remoto só traz vantagens?Em 2023, algumas transfomações sociais geradas pelas medidas adotadas durante a circulação mais ativa do vírus, entre 2020 e 2022, foram incorporadas definitivamente ao cotidiano de milhões de pessoas em todo o mundo. Uma delas é o trabalho remoto, que em alguns países tornou-se comum para algumas categorias da população.Trabalhar em casa, entretanto, não traz apenas vantagens. Para muitas mulheres, que sofrem de carga doméstica e mental no dia a dia, ele pode ser uma armadilha, alerta a psicóloga francesa Aline Nativel Id Hammou, autora do livro “Burn Out Parental”.“Em casa, todas as tarefas da vida cotidiana ficam 'gravitando' em torno do computador, enquanto trabalhamos. Podemos, às vezes, nos sobrecarregar. Na hora do almoço, por exemplo, como não estamos na empresa, há a tentação de se ‘obrigar' a fazer as tarefas domésticas, ou do cotidiano, pelo fato de estar em casa”, alerta.Ao longo de 2023, o trabalho remoto vem sendo mantido em muitas áreas, mas muitas empresas também estão exigindo o retorno dos seus funcionários para o escritório.Uso do Ozempic preocupa autoridadesOutro assunto que virou notícia em 2023 é o Ozempic, um medicamento contra o diabetes lançado em 2019, que controla a glicose e ajuda na perda de peso. Por ser eficaz contra o emagrecimento, ele passou a ser usado de maneira deturpada – uma prática que se popularizou e viralizou em vídeos no TikTok. Por conta disso, muitas pessoas têm usado o remédio sem indicação médica, explica Rodrigo Lamounier, endocrinologista professor da UFMG (Universidade Federal de Minas Gerais).“Ele melhora a eficiência da ação da insulina nas pessoas que têm diabetes e é muito eficaz em melhorar o controle da glicose”, diz. Além disso, o remédio tem o efeito de gerar saciedade. “Ele causa um retardamento do esvaziamento gastrointestinal, provocando saciedade. E age também no hipotálamo, no centro da fome, provocando inibição da fome, perda de apetite e diminuindo, assim, a ingesta alimentar”, diz, ressaltando que o remédio deve ser usado em casos específicos.Cresce incidência do câncer do intestinoO aumento da incidência do câncer do intestino, o segundo que mais mata em todo o mundo, também foi destaque durante ano de 2023. Se descoberto no início, o câncer colorretal tem 100% de chances de cura, explicou o gastroenterologista francês Michel Ducreux, do instituto francês Gustave Roussy, um dos maiores centros de combate ao câncer no mundo, situado em Villejuif, nos arredores de Paris.“O teste imunológico permite a detecção de 80% dos cânceres e dos tumores benignos, que estão se 'modificando', crescendo e que vão provavelmente se transformar em cânceres. Neste caso, podemos, durante a colonoscopia, retirar os pólipos e evitar o câncer. É uma política que pode trazer resultados, mas se houver adesão”, ressalta.Clones de cânceres podem ajudar pacientes com tumores gravesEm busca de soluções contra cânceres e tumores graves, cientistas do mundo todo trabalham nos laboratórios em estudos que buscam, cada vez mais, individualizar os tratamentos.No Instituto Gustave Roussy, um grupo de pesquisadores, liderado pela especialista em gastroenterologia, genética e biologia molecular, Fanny Jaulin, fabrica em laboratório cópias biológicas de cânceres a partir das células dos pacientes. O objetivo é lutar contra tumores em fase terminal, propondo tratamentos individualizados.“Nosso desafio é recriar os tumores dos pacientes com câncer, com foco em novos tratamentos. Nós nos especializamos na criação desses organóides, cultivados em laboratório a partir de uma pequena biópsia, feita com uma simples agulha”.Brasil abandona uso da AstraZenecaA RFI também divulgou em primeira mão, neste ano, a notícia de que desde o final de 2022 o Ministério da Saúde recomenda que as vacinas de vetor viral, como a AstraZeneca e a Janssen, não sejam mais aplicadas como reforço contra a Covid-19. A recomendação vale a partir da terceira dose, na população com menos de 40 anos. O motivo da decisão é o risco aumentado de trombose, principalmente em mulheres.Até janeiro de 2002, a vacina já tinha sido usada em cerca de 115,6 milhões de pessoas no país. A notícia foi confirmada pelo infectologista Julio Croda, especialista da Fiocruz, professor da Universidade Federal do Mato Grosso do Sul e da Faculdade de Saúde Pública de Yale, nos Estados Unidos.“O Brasil tem, dentro do seu programa nacional de imunização, um sistema de farmacovigilância que é justamente feito para avaliar os eventos adversos associados às diversas vacinas. Através desse monitoramento, foi identificado um aumento de risco, eventualmente, para trombose, principalmente em pessoas jovens, abaixo de 40 anos e mulheres”, explicou o infectologista. “Isso é bastante similar ao que foi identificado em outros países, como no Reino Unido, no caso da vacina da AstraZeneca, e nos Estados Unidos, no caso da vacina da Janssen.”Os segredos do microbiotaA Ciência está apenas começando a compreender como o microbiota, os micróbios (incluindo bactérias, vírus e fungos) que moram no nosso corpo, principalmente no intestino, atuam nas funções orgânicas. Estudos mostram que eles podem estar envolvidos até mesmo em processos cerebrais e no desenvolvimento da depressão.A oncologista brasileira Carolina Alves Costa Silva, integra há cinco anos uma equipe do instituto francês Gustave Roussy e estuda o microbiota humano. Em um dos seus projetos, a pesquisadora busca entender a influência sua na resposta aos tratamentos contra o câncer, e, a longo prazo, como pode se tornar um aliado na prevenção da doença. “Há evidências de que essas bactérias e outros micro-organismos podem atuar na diminuição da resposta imune e impedir que alguns tipos de tratamento contra o câncer funcionem bem”, disse Carolina em entrevista à RFI.Vacina freia cânceres da cabeça e do pescoçoNeste ano, nosso programa deu destaque para vacina terapêutica TG4050, da biotech francesa Transgene. O produto é uma nova arma, inédita, na luta contra a recaída de cânceres precoces, e geralmente graves, da cabeça e do pescoço e tem dado bons resultados, como explicou o CEO da empresa, Alessandro Riva, à RFI.“Fizemos um estudo randomizado de fase 1 e comparamos os pacientes que tinham recebido a nossa vacina individualizada e personalizada com outros que não receberam. Por hora não temos recaídas, e esse follow-up, ou acompanhamento, começa a ser considerável. Os pacientes tratados na fase 1 têm uma resposta imunitária contra as proteínas e mutações que selecionamos, e na qual estão baseadas as vacinas", diz. "É uma reviravolta para a empresa, mas também em relação a tudo que envolve vacinas individualizadas e personalizadas.”O cérebro fabrica falsas memóriasOutro destaque em 2023 é o avanço dos estudos sobre como cérebro é capaz de criar falsas memórias. Ao longo das últimas décadas, diversas pesquisas científicas comprovaram que nossa mente pode fabricar vivências, incluindo detalhes que nunca existiram. Este foi um dos temas dos nossos programas em 2023. O neurobiologista Pascal Roullet, da Universidade Paul Sabatier, em Toulouse, é um dos maiores especialistas franceses no assunto. Em entrevista à RFI, ele explicou como nosso cérebro arquiva e transforma uma memória antes dela ser definitivamente arquivada. "A informação é tratada em termos neurobiológicos. Nos animais, sabemos que esse processo vai demorar entre seis e dez horas, o tempo necessário para que essa memória possa ser armazenada na memória de longo prazo.”Vírus da Covid-19 contamina o sistema nervoso centralNeste ano de 2023, diversas pesquisas sobre o vírus da Covid-19 tentaram entender seu funcionamento. Uma delas foi feita por uma equipe do Instituto Pasteur e publicada na revista Nature Communications. O médico veterinário brasileiro Guilherme Dias de Melo integra o projeto desde 2020. O objetivo era verificar se o SARS-CoV-2 era capaz de infectar os neurônios e provocar algum problema no cérebro, o que acabou sendo confirmado pela equipe.“A mensagem principal é: o SARS-CoV-2 é capaz de infectar os neurônios e utilizá-los como uma rota de acesso ao sistema nervoso central. E a manifestação clínica na fase aguda não necessariamente vai influenciar uma manifestação clínica na fase longa.”

In this podcast, UROONCO RCC associate editor Dr. Teele Kuusk (GB) talks with medical oncologist Prof. Laurence Albiges (FR), Head of the Department of Oncology at Gustave Roussy, about her abstract: Belzutifan versus everolimus in participants with previously treated advanced clear cell renal cell carcinoma (ccRCC): Randomised open-label phase III LITESPARK-005 study.Prof. Albiges discusses the study results she presented at ESMO 2023. LITESPARK-005 established HIF-2a inhibition as a novel therapeutic mechanism of action in advanced clear cell RCC. Belzutifan demonstrated a statistically significant improvement in progression-free survival (PFS) and objective response rate versus everolimus.LITESPARK-005 is the first positive phase 3 study in patients with advanced kidney cancer following immune checkpoint and anti-angiogenic therapies.Prof. Albiges also answers a question about why everolimus was used as a comparator in this trial. Looking at the future, she shares her vision of how Belzutifan (the new HIF inhibitor) can be used for metastatic kidney cancer patients.Lastly, Prof. Albiges talks about what trials are ongoing that will position Belzutifan on the treatment line. Belzutifan is currently being studied in combination in second-line, first-line, and adjuvant settings in phase 3 studies.

Two experts in medical oncology explore the latest developments in metastatic colorectal cancer in this episode of the EMJ podcast. Elena Élez, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain; and Michel Ducreux, Gustave Roussy, Villejuif, France, and Paris-Saclay University, France, discuss current treatment guidelines for patients with mCRC BRAF V600E mutation. This podcast has been funded by Pierre Fabre; the position and discussions might not represent the position of Pierre Fabre.

durée : 00:07:34 - La Question du jour - par : Marguerite Catton - L'annonce, faite hier, des résultats obtenus par un vaccin thérapeutique dans le traitement du cancer du poumon génère un certain espoir. Comment fonctionne un tel traitement ? Comment notre système immunitaire pourrait-il êtres mis à contribution dans la lutte contre la maladie ? - invités : Fabrice Barlesi Directeur médical de l'institut Gustave Roussy

durée : 02:28:32 - Le 7/9.30 - par : Nicolas Demorand, Léa Salamé - Cédric Sapin-Defour, écrivain, auteur de Son odeur après la pluie (Stock), Fabrice Barlesi, directeur général de Gustave Roussy, Sarah Watson et Delphine Loirat, oncologues à l'Institut Curie, et Michèle Fitoussi, journaliste, autrice de La famille de Pantin (Stock), sont les invités de la matinale.

durée : 00:24:02 - L'invité de 8h20 : le grand entretien - par : Nicolas Demorand, Léa Salamé - Fabrice Barlesi, directeur général de Gustave Roussy, spécialiste du cancer du poumon, Sarah Watson, oncologue à l'Institut Curie, spécialiste des cancers rares, et Delphine Loirat, oncologue médical à l'Institut Curie, spécialiste du cancer du sein, sont les invités du Grand entretien.

durée : 00:24:02 - L'invité de 8h20 : le grand entretien - par : Nicolas Demorand, Léa Salamé - Fabrice Barlesi, directeur général de Gustave Roussy, spécialiste du cancer du poumon, Sarah Watson, oncologue à l'Institut Curie, spécialiste des cancers rares, et Delphine Loirat, oncologue médical à l'Institut Curie, spécialiste du cancer du sein, sont les invités du Grand entretien.

Mardi 4 avril , François Sorel a reçuMathias Fraisse, directeur technologies du groupe Indigo ; Hugues Gendre, directeur des Systèmes d'informations de l'UCPA ; Julien Simon, évangéliste technique chez Hugging Face ; Philippe Roques, directeur général Adjoint en charge du numérique et des opérations chez CLS ; Charlotte Robert, maître de conférences universitaires en physique médicale à Gustave Roussy ; Robert Marino, président de Qubit Pharmaceuticals ; Thierry Bonhomme, directeur technique digital de E-TF1 ainsi que Stéphane Deux, directeur digital et technologies du groupe Transdev, dans l'émission Tech & Co sur BFM Business. Retrouvez l'émission du lundi au jeudi et réécoutez la en podcast.

Charlotte Robert, maitre de conférences universitaire en physique médicale à Gustave Roussy, et Robert Marino, président de Qubit Pharmaceuticals, étaient les invités de François Sorel dans Tech & Co, ce mardi 4 avril. Ils se sont penchés sur l'optimisation du domaine médical par l'intelligence artificielle, notamment les recherches contre le cancer, ainsi que la fabrication de médicaments, sur BFM Business. Retrouvez l'émission du lundi au jeudi et réécoutez la en podcast.

Un matin, à l'institut Gustave Roussy de Villejuif, la docteure Mansouriah Merad reçoit une femme de cinquante ans. Depuis deux jours, cette patiente atteinte d'un cancer du sein pousse des cris de douleur. Étonnamment, les examens sont satisfaisants et aucun problème apparent ne permet d'expliquer ses souffrances actuelles. Au départ, la médecin pense qu'il s'agit d'une détresse psychologique. Pour cause, cette mère de deux enfants affronte une récidive agressive de son cancer, ce qui pourrait expliquer l'apparition de troubles du comportement. Pourtant, son état clinique se dégrade et les questions tourbillonnent dans la tête du docteure Merad...

This episode of Lung Cancer Considered is part of our series on FDA approvals of new lung cancer therapies. Today, host Dr. Stephen Liu discusses the EMPOWER-Lung 3 regimen of the PD-1 inhibitor cemiplimab with first-line platinum doublet chemotherapy for advanced NSCLC. This regimen was approved by the FDA on November 8, 2022. His guests are Dr. Jordi Remon, a thoracic medical oncologist who had previously practiced at Hospital de Mataro in Barcelona. He is now part of the esteemed thoracic unit at Gustave Roussy in Paris and the secretary of the Lung Cancer Group of EORTC. Joining Dr. Remon is Dr. Isabel Preeshagul, a thoracic medical oncologist and Assistant Attending with Memorial Sloan Kettering. She is also the chair of the Education and Engagement Committee of the Lung Cancer Research Foundation.

durée : 00:15:06 - Journal de 12h30 - Les bâtiments historiques du Vieux-Lille, le cœur de la ville du Nord, s'avèrent fragiles - trop fragiles. Dans la nuit de samedi à dimanche, de nouveaux immeubles ont été évacué en urgence à la demande des pompiers, après la découverte de fissures. - invités : Catherine Hill épidémiologiste, chercheuse à l'Institut de cancérologie Gustave Roussy, a fait partie du conseil scientifique de l'Agence nationale de sécurité du médicament et des produits de santé, écrit régulièrement pour la revue Sciences et Pseudo-Sciences

durée : 00:15:06 - Journal de 12h30 - Les bâtiments historiques du Vieux-Lille, le cœur de la ville du Nord, s'avèrent fragiles - trop fragiles. Dans la nuit de samedi à dimanche, de nouveaux immeubles ont été évacué en urgence à la demande des pompiers, après la découverte de fissures. - invités : Catherine Hill épidémiologiste, chercheuse à l'Institut de cancérologie Gustave Roussy, a fait partie du conseil scientifique de l'Agence nationale de sécurité du médicament et des produits de santé, écrit régulièrement pour la revue Sciences et Pseudo-Sciences

La maladie des Enfants de la Lune est une maladie génétique qui prive ceux qui en sont atteints de s'exposer aux rayons ultraviolets. Lorsqu'ils sortent, enfants et adultes doivent protéger chaque millimètre de leur peau et porter un casque ressemblant à celui d'un cosmonaute, sous peine de voir leur peau développer des lésions cancéreuses. Nihal, 23 ans, est atteinte de cette maladie. Le Professeur Alain Sarasin, directeur de recherche émérite au CNRS et à l'institut Gustave Roussy à Villejuif, répond aux questions sur ce sujet.

Un matin, à l'institut Gustave Roussy de Villejuif, la docteure Mansouriah Merad reçoit une femme de cinquante ans. Depuis deux jours, cette patiente atteinte d'un cancer du sein pousse des cris de douleur. Étonnamment, les examens sont satisfaisants et aucun problème apparent ne permet d'expliquer ses souffrances actuelles. Au départ, la médecin pense qu'il s'agit d'une détresse psychologique. Pour cause, cette mère de deux enfants affronte une récidive agressive de son cancer, ce qui pourrait expliquer l'apparition de troubles du comportement. Pourtant, son état clinique se dégrade et les questions tourbillonnent dans la tête du docteure Merad...

Axiom Catalyst is live from Gustave Roussy! Hafiz Sikder joins Dr. Barlesi and the leading cancer treatment team in Villejuif, France for a discussion on the future of oncology.

Videos: 1.Covid has torn apart our social fabric (Feat. Dr. Matt Strauss) 2.  A Christian Response to Wokeness (FULL VIDEO) | Noelle Mering | Leadership Institute (21:51) 3.  NBC News just SMEARED real journalists in shameful hit piece | Redacted with Clayton Morris (22:00) 4. COME HELL OR HIGH WATER! Four minutes of WOW! (talking about the shootings and blame)   Vitamin D deficiency directly linked to dementia University of South Australia, June 14, 2022 Dementia is one of the major causes of disability and dependency among older people worldwide, affecting thinking and behaviors as you age. But what if you could stop this degenerative disease in its tracks? A world-first study from the University of South Australia could make this a reality as new genetic research shows a direct link between dementia and a lack of vitamin D. Investigating the association between vitamin D, neuroimaging features, and the risk of dementia and stroke, the study found: low levels of vitamin D were associated with lower brain volumes and an increased risk of dementia and stroke genetic analyses supported a causal effect of vitamin D deficiency and dementia. in some populations as much as 17% of dementia cases might be prevented by increasing everyone to normal levels of vitamin D (50 nmol/L). Flaxseed supplements linked to improved blood pressure: Meta-analysis University of Medicine and Pharmacy (Romania), June 9, 2022 Supplements of flaxseed may effectively management blood pressure, says a new meta-analysis of 15 clinical trials. Data from 1,302 participants indicated that flaxseed supplements are associated with significant reductions in both systolic and diastolic blood pressure of about 2.85 mmHg and 2.39 mmHg, respectively. “The results obtained in the present meta-analysis – a decrease of 2.85/2.39 mmHg after flaxseed supplementation – might be valuable for the hypertension management using nutraceuticals, since Heart Outcome Evaluation study demonstrated that a 3.3/1.4 mmHg reduction was associated with a 22% decline of relative risk of cardiovascular mortality,” wrote scientists from Romania, Iran, Australia and Poland in Clinical Nutrition . The scientists also report that supplementation for longer than 12 weeks resulted in even greater reductions in systolic and diastolic blood pressure of 3.10 mmHg and 2.62 mmHg, respectively, compared to trials of shorter duration. The potential biological mechanism are not completely understood, said the researchers, but could be linked to the lignan content of flaxseed. Specifically, a lignan named SDG is known to be an angiotensin-converting enzyme (ACE) inhibitor. ACE inhibitors work by inhibiting the conversion of angiotensin I to the potent vasoconstrictor, angiotensin II, thereby improving blood flow and blood pressure. Finally, an arginine-rich protein fraction (KCl-F1) from flaxseed may also impact blood pressure. Flaxseed powder supplements were found to affect systolic blood pressure (SBP) and diastolic blood pressure (DBP), whereas flaxseed oil preparations only affected DBP. On the other hand, lignan extracts was not associated with any changes in SBP and DBP, they said. Keep calm and carry on — for the sake of your long-term health Penn State University, June 9, 2022 Reacting positively to stressful situations may play a key role in long-term health, according to researchers. In a study measuring adults' reactions to stress and how it affects their bodies, researchers found that adults who fail to maintain positive moods such as cheerfulness or calm when faced with the minor stressors of everyday life appear to have elevated levels of inflammation. Furthermore, women can be at heightened risk. Nancy Sin, in the Center for Healthy Aging, Penn State and her colleagues showed that the frequency of daily stressors, in and of itself, was less consequential for inflammation than how an individual reacted to those stressors. “A person's frequency of stress may be less related to inflammation than responses to stress,” said Sin. “It is how a person reacts to stress that is important.” In the short-term, with illness or exercise, the body experiences a high immune response to help repair itself. However, in the long term, heightened inflammatory immune responses may not be healthy. Individuals who have trouble regulating their responses may be at risk for certain age-related conditions, such as cardiovascular disease, frailty and cognitive decline, Sin said. “To our knowledge, this paper is the first to link biomarkers of inflammation with positive mood responses to stressors in everyday life,” said Jennifer E. Graham-Engeland, associate professor of biobehavioral health, Penn State. For breast cancer prevention, diet quality matters Healthy, plant-based diet linked with lower cancer risk for postmenopausal women  Paris-Saclay University (France), June 14, 2022 Research shows that what we eat can influence our cancer risk, but it's not always clear which foods or dietary patterns are best for cancer prevention. Results from a new study suggest that the quality or overall healthiness of a person's diet may be key. The study, based on data from over 65,000 postmenopausal women who were tracked for more than two decades, found that a healthy plant-based diet was linked with a 14% lower risk of breast cancer while an unhealthy plant-based diet was linked with a 20% higher risk of breast cancer. The findings were consistent across all breast cancer subtypes. “These findings highlight that increasing the consumption of healthy plant foods and decreasing the consumption of less healthy plant foods and animal foods might help prevent all types of breast cancer,” said Sanam Shah, at Paris-Saclay University, Gustave Roussy, France, the study's lead author.  Previous studies have examined cancer risks associated with various dietary patterns such as the Western diet, the Mediterranean diet and vegetarian diets. Although some studies suggest diets with less or no meat consumption offer health benefits, results have been somewhat mixed. For the new study, researchers focused on differentiating between healthy plant-based foods — such as whole grains, fruit, vegetables, nuts, legumes, vegetable oils and tea or coffee — and plant-based foods the study categorized as less healthy including fruit juices, refined grains, potatoes, sugar-sweetened beverages and desserts. Regular exercise beneficial in suppressing inflammation in rheumatic disease Exercise results in physiological changes that decrease inflammation on a local and systemic level Ohio State University, June 12, 202 Research findings suggest that exercise transiently suppresses local and systemic inflammation, reinforcing the beneficial effects of exercise and the need for this to be regular in order to achieve clinical efficacy in rheumatic disease. These new research findings focused on the physiological changes created by exercise and their impact on inflammation. The researchers have found that exercise generates a true biological response and induces changes on a molecular level that stimulate anti-inflammatory effects. This in-vivo study measured the regulation and activation of NF-kB* in mice. NF-kB, a protein complex that controls many genes involved in inflammation, is found to be chronically active in many inflammatory diseases, such as inflammatory bowel disease and arthritis. The effect of exercise on the inhibition of NF-kB activation was identified as a transient effect, lasting only 24 hours after exercise.The role of exercise in inhibiting NF-kB activation was linked to the suppression of multiple pro-inflammatory cytokines.  Keeping the faith – or your willingness to push yourself – as you grow older Norwegian University of Science and Technology, June 14, 2022 So you could have become a pro footballer when you were younger, you say? Or really good at chess? Perhaps a world-renowned chef? Well, maybe not anymore, we think as we get older. And maybe that's actually okay. A research group has investigated how important the motivational factors for becoming really proficient at a skill change over the years. “We wanted to see how the passion, grit and belief that you'll succeed at getting better – your growth mindset – change with age and in relation to gender,” says Hermundur Sigmundsson, a professor at the Norwegian University of Science and Technology's (NTNU) Department of Psychology. “The passion for what you used to burn for declines. And so does the belief that you can succeed at becoming really good at it,” says Professor Sigmundsson. But this is where it is important to take hold of yourself and not give up. You might not become a world champion in anything, but you could still get really proficient if you go for it. Or at least better. “That's when it's important to maintain a growth mindset. You can't stop believing in growth even though you're getting older,” says Sigmundsson. “Passion and a growth mindset decrease with age, but the willingness to persevere increases if we look at the elderly population as a whole,” says Sigmundsson.

Les cancers chez l'enfant constituent la deuxième cause de mortalité pédiatrique en France.  Selon l'OMS, le cancer est diagnostiqué chaque année chez environ 300 000 enfants âgés de 0 à 19 ans. Les formes les plus fréquentes sont la leucémie, les cancers du cerveau, les lymphomes et les tumeurs solides, telles que le neuroblastome et la tumeur de Wilms. Comment les diagnostics sont-ils établis ? Comment prendre en charge la douleur ? Quels traitements existent ? Comment gérer l'après-cancer ? Dr Dominique Valteau-Couanet, cheffe du Département de Cancérologie de l'enfant et de l'enfant de l'Hôpital Gustave Roussy, à Villejuif, en région parisienne Dr Aleine Budiongo, onco-pédiatre, responsable de l'Unité d'Oncologie pédiatrique aux Cliniques Universitaires de Kinshasa en RDC Pr Pierre Bey, président du Groupe Franco-Africain d'Oncologie Pédiatrique (GFAOP). Professeur émérite de Cancérologie-Radiothérapie de l'Université de Lorraine, ancien directeur de l'Hôpital de l'Institut Curie, à Paris. Directeur médical et secrétaire général de l'Alliance Mondiale contre le Cancer Magali Bidoux, maman de Noa, atteint de gliome des voies optiques Jima Rachiratou,13 ans, qui a eu à 6 ans un Rhabdomyosarcome (la tumeur maligne la plus fréquente chez l'enfant et l'adolescent).

Quels arguments je présente à mon patient pour un traitement par radiothérapie dans le cadre d'un cancer de la prostate localisé de risque intermédiaire Quels sont les intérêts de la radiothérapie dans le cancer de prostate intermédiaire ? Comment présentez vous le déroulement et les possibles effets secondaires de la radiothérapie à vos patients ?Quel impact du premier traitement sur la récidive et sa prise en charge ? Pourquoi favoriser une consultation en radiothérapie avant la prise de décision ?Pr Pierre Blanchard, professeur oncologie-radiotherapie à l'institut Gustave Roussy à Villejuif répond à toutes vos questions ! L'orateur n'a pas reçu de rémunération pour la réalisation de cet épisode. Cet épisode a été réalisé grâce au soutien institutionnel des Laboratoires Bayer.Certaines données publiées peuvent ne pas avoir été validées par les autorités de santé françaises.La publication de ce contenu est effectuée sous la seule responsabilité de l'éditeur et de son comité scientifiqueMusique du générique : Via AudioNetwork Responsable projet AFUF : Dr Benjamin PradèreProduction : La Toile Sur Ecoute Voir Acast.com/privacy pour les informations sur la vie privée et l'opt-out.

Dr. Shannon Westin and Dr. Antonio Di Meglio discuss the issue of fatigue among cancer survivors.   Transcript [MUSIC PLAYING] Speaker 1: The guest on this podcast episode has no disclosures to declare. Shannon Westin (Dr. Westin): Hello, everyone. And welcome to another episode of JCO After Hours. This is our podcast where we get in depth with different authors and experts about wonderful manuscripts that are being published in the Journal of Clinical Oncology. And today it is my great pleasure to be accompanied by Dr. Antonio Di Meglio, who is a Medical Oncologist and a Physician Scientist at the Breast Cancer Survivorship Research Program in Gustave Roussy in France. So welcome, Dr. Di Meglio. Dr. Antonio Di Meglio (Dr. Di Meglio): Thank you so much for having me here today. Dr. Westin: We're so excited to have you. We're going to be talking about your article, which is due to be published January 21, 2022, in the Journal of Clinical Oncology titled “The Development and Validation of a Predictive Model of Severe Fatigue After Breast Cancer Diagnosis: Toward a Personalized Framework in Survivorship Care.” And before we get started, I would just note that none of the guests have any relevant conflicts to disclose. With that, let's get into it. I was so excited to read this paper because this such a critical problem for our patients. And I'm a gynecologic oncologist, but this goes across all—surgical, medical, any field that we could even think of. So why don't you start off by telling us what led you to explore the problem of cancer-related fatigue? Dr. Di Meglio: Cancer related fatigue is one of the most troublesome and prevalent symptoms among cancer survivors and including breast cancer survivors. So several reports reported on the prevalence of cancer-related fatigue reporting up to 50% of patients in some studies with fatigue after cancer and the end of treatment. But what we know is that at least one in three cancer survivors experience fatigue symptoms at some point over time. In addition, we do know that fatigue is particularly distressing and impactful as it can impact on daily living and functioning and overall quality of life. Also, there's an important impact on social function and return to work after cancer and adherence to oral therapies, especially in the age event setting in breast cancer survivors. Finally, we also know that fatigue is often inadequately addressed and often neglected because of lack of time, lack of resources. Definitely, we should do more in the clinic for our patients struggling with fatigue. Dr. Westin: This is such an important issue. I think the elephant in the room here is how do we grade this and how do you advocate for a busy clinician in the clinic seeing 30, 40, 50 patients in a day. How do we really assess this? What's the best way to determine if somebody has cancer-related fatigue or is at risk? Dr. Di Meglio: Thank you for this important point. In clinical research, we do have a number of instruments that we can use to grade fatigue, including the European Organization For Research and Treatment of Cancer, Quality of Life Questionnaires that are the questionnaires that we used in our study. These are instruments that our patient reported. So we really can hear patient voices and patient perspectives in terms of their own symptoms. And some of the items that we use, for example, for cancer-related peak do not take much time to be asked also in a basic clinic. For example, we did use the EORTC QLQ Questionnaire C30 to score global fatigue. So we basically asked patient three questions: whether they needed to rest, they felt weak, or they felt tired, typical week. And these gave us the score of what we called global fatigue. There's also other instruments and companion models that we can use to assess more specifically dimensions of fatigue, including the physical, emotional, and cognitive dimension of fatigue. It is true that in our busy day in clinics, this may not be easily implementable. But what I believe is that if we never ask patients the right questions, patients will never tell us the right answers that we can proactively use to address the symptoms. So even just assessing fatigue in a general way, asking whether their energy levels changed over the past weeks, if they know that any change that was related to the treatment or any tiredness that was not really related to their usual activities or that was impactful on daily activities, this should trigger clinicians to ask more and more and to find solutions for the problem. So just ask the questions, even though the assessment may not be comprehensive and extensive, but this can be very important and meaningful for the patients. Dr. Westin: I think that's a really critical point because using validated instruments is obviously our aspirational goal and our attempted standard of care, but on a day in and day out clinic, it can be hard to have patients filling out a survey or something that may take a longer time. So I think that's a critical point is pull out these critical questions so that you can identify these issues and address them for your patient. When we're talking about grading fatigue, say in the clinic, would you recommend maybe choosing one? How long do these types of assessments take? Is this something feasible for a busy oncologist in clinic? Dr. Di Meglio: So definitely our study calls a little bit for the implementation of these instruments that are being used in mostly in clinical research over the past decades, also in the clinical practice. These are patient reported instruments that really can give us a sense of how impactful fatigue is in daily living and functionality. And when we grade fatigue using this instruments such as the EORTC scores, we can really capture fatigue that is defined as severe, meaning fatigue that really impacts on quality of life and needs to be absolutely addressed by clinicians and needs interventions urgently. Dr. Westin: That makes a lot of sense. Why don't we get into a little bit more around your study using these specific instruments? Like what was the patient population? Run us through that. Dr. Di Meglio: So this study was performed using CANTO data. CANTO is a longitudinal cohort of breast cancer survivors. Patients that were initially diagnosed with Stage 1, 2, and 3 breast cancer. It's a French cohort that enrolled patients across 26 centers in France starting in 2012. And at this point, the cohorts included over 10,000 patients, and this study was performed using a first split of the cohort for the development models that included around 6,000 patients overall, and then 3000 patients for the validation of these models. So the availability of data of fatigue was really the driver of the patient population that we used for this study. So we used all available questionnaires of EORTC QLQ-C30 therapy, to which we assessed our primary outcome of interest, which was global fatigue. CANTO has a first assessment at baseline, that is a breast cancer diagnosis, meaning before the initiation of any cancer treatment. Meaning surgery, chemotherapy, radiation therapy, therapy of any type. Then we perform longitudinal assessment at one year, two years, four years after diagnosis. There is a fifth assessment at five years after diagnosis for which data are not mature yet, but for the present study, we use data until four years after diagnosis. So our interest was to understand which are the risk factors for severe fatigue, primarily at two years after diagnosis. Then we also developed and validated models for severe fatigue at four years after diagnosis. So our interest was to identify a population of patients that since diagnosis can be flagged as being at high risk of developing severe fatigue after diagnosis and of course after treatment for breast cancer. This is a population of early-stage breast cancer survivors. So I really want to highlight that these models were developed and validated for survivors that are free of cancer at the time of fatigue assessment. So whether they experience cancer recurrence, metastasis, second cancers, they exit cohort. So this is purely early stage survivors of breast cancer. Dr. Westin: Thank you for that clarification. And I think it is important to really focus in on these populations because we are going to see differences in the occurrence of fatigue across patients that are actively receiving treatment in the continuum of recurrence or later in survivorship. So thank you for that clarification. I think that that really makes a lot of sense. And this is a population that's extremely large and very critical to our management. So why don't you tell us a little bit about what were some of the factors that you found to be associated with severe fatigue in your cohort? Dr. Di Meglio: So our models allowed us to identify a number of factors that are risk factors for severe fatigue after breast cancer diagnosis. So first of all, the most consistent and the strongest factors that was identified as associated with post-treatment fatigue was pre-treatment fatigue. So patients that are already severely fatigued at diagnosis have much higher likelihood of reporting severe fatigue also years after diagnosis. This was identified as a risk factors also in previous literature as it may set stage for post-treatment fatigue because maybe there are biological disruptions or bio-behavioral disruptions that are already present at the moment of diagnosis. So they keeping there and they put patients at higher risk of post-treatment fatigue. In addition to this, we found that clinical factors such as younger age was associated with high risk of fatigue after treatment. And there are also behavioral risk factors.  Patients that are current smokers at the time, active smokers at the time of the diagnosis, as well as patients with a higher body mass index. They are all at higher risk of persistent, severe fatigue after diagnosis. Finally, we also identify concomitant symptom clusters that are associated with a higher risk of severe fatigue. And these include emotional distress and particularly anxiety, insomnia. So sleep disturbances and pain at the moment of diagnosis. These are the risk factors that emerged for the models of severe fatigue at year two after diagnosis. But when we look further in to the risk factors of fatigue at year four after diagnosis, we consistently identified premenopausal status that is very consistent with younger age and also received of hormonal therapy. So our assumption was that longer these patients are into hormonal therapy, the higher the risk of severe fatigue becomes. So even though our models at Tier 4 are to be considered exploratory, we believe that they give us an additional insight into which treatment related factors would be associated with higher risk of fatigue. Dr. Westin: You'll have to forgive me because my knowledge of early breast cancer is very minimal. So for these patients, did any of them receive chemotherapy and was that at all relevant or is this a population that generally got maybe surgery and hormonal therapy? Dr. Di Meglio: So in the population that we study and consistent with the stage distribution, over 50% of the patients received chemotherapy. Almost 80% and more received hormonal therapy. So we really investigated the impact of all treatment types on the risk of fatigue. And we did find a differential impact of different treat modalities on the risk of fatigue.  I liked this in the paper because this is Year 1 model while our main interest was Year 2 after diagnosis models. But we did find an impact of chemotherapy on the risk of fatigue at one year after diagnosis, meaning the closest time point that we have to the end of primary treatment, including chemotherapy. And this effect seems to produce over time, and we don't find it in models at Year 2 and Year 4 anymore. So it's less consistent and it's not confirmed invalidation models. In contrast, the impact of hormonal therapy was much stronger at Tier 2 was confirmed at Tier 4. So this gives us the sense that the longer patients are on hormonal therapy, the higher risk of severe fatigue becomes for them. And this is also consistent with previous data from other literature. For example, Pat. A Ganz in The Mind-Body Study had demonstrated that hormonal therapy can delay the recovery from treatment-related symptoms that are usually associated with chemotherapy. And in a previous study using the CANTA cohort, we also had found an impact of hormonal therapy on the recovery of symptoms and functions that usually get better over time, for example, emotional function or future perspectives whose recovery seems to be delayed among patients that receive hormonal therapy. Dr. Westin: Well, this is great, understanding who might be at risk and trying to identify these patients. I guess the natural question is next. Like what do we do? What are our available options to treat cancer-related fatigue or even prevent it? Dr. Di Meglio: I think this is a great point and that definitely leads me to trying to understand and to explain what is the implementation of our models in clinic. So what we envision would be a clinical care setting where our models would aid clinicians to be more aware about the problem of fatigue and about ways that we have to better describe fatigue among our patients and better identify its risk factors. So let's imagine that we have an incoming new patient in our clinic and we assess the risk of severe fatigue in this patient after treatment. By assessing risk factors, we also assess fatigue at the moment of diagnosis. And we do know that in this analysis, we found that almost 25% of patients present already with severe fatigue diagnosis, and a patient like this needs to be already treated for the symptoms that he or she is reporting. So we do have now available interventions to treat fatigue when it's already present. So first of all, increasing physical activity. We also have psychosocial interventions, including cognitive behavioral therapy and psychoeducational therapies that we know that work for cancer-related fatigue and some mind-body interventions, such as yoga demonstrated some activity for cancer-related fatigue. Other approaches include mindfulness based approaches or acupuncture that can be offered to patients that already present with severe fatigue and diagnosis, particularly also the assessment of all concomitant conditions, such as nutritional imbalances should be performed in detail at the moment of diagnosis. In contrast, we might find a patient that doesn't have symptoms of severe fatigue at the moment of diagnosis, but definitely our models can increase the awareness of the risk factors and highlight a way to recognize symptoms that can hurl out the onset of fatigue and facilitate the management of risk factors and the referral to dedicated consultations or to dedicated specialists that can take care of such risk factors. In fact, the majority of risk factors that we identified are modifiable, such as we can address as tobacco use. We can address overweight and obesity as well as we can address specific symptom clusters that usually come in conjunction with fatigue, sleep problems, pain, emotional distress. We do have interventions available for all these symptoms. Of course, there is an important question there arises here, that is by addressing all three factors, is fatigue preventable at this point. I am not sure that we have the answer yet for this question at this point, but definitely by addressing risk factors, by addressing behavioral problems, we are addressing survivorship problems in a more comprehensive way. That is the direction in which survivorship care should probably go today. So as next steps, definitely we should look towards the implementation of risk models in clinical practice towards planning more meaningful prevention trials for problems such as cancer-related fatigue. And in addition, I believe that cancer-related fatigue is just an example of very common and prevalent and distressing symptoms that are not often taken care of or sufficiently taken care of in the clinic. So this can serve as a case study, as a model to expand our no also of other symptoms and of other survivorship issues that our patients and survivors may face. Dr. Westin: Well, I just want to commend you. These are really such exciting work, and I know it's something that will be implemented in the breast cancer community but also beyond. And I'm hoping that some of our other cancer-type survivorship experts are listening right now and getting inspired by your work. So we can look at this in other tumor types and really help implement this across the world. So thank you so much again for your amazing work. Thank you so much for taking the time to meet with me today, and best of luck in moving this forward. Dr. Di Meglio: Thank you so much, Dr. Westin. It was great to be here with you today. Dr. Westin: Thank you so much to all our listeners. We are always so grateful that you tune in and we can't wait to bring you discussion of our next manuscript. Have a great one. [MUSIC PLAYING] Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

Il y a un an, Emilie, notre co-présentatrice apprenait qu'elle était atteinte d'un cancer du sein Triple Négatif. Nous sommes revenus avec elle aujourd'hui sur cette années qui vient de s'écouler. C'est l'occasion de faire un oint et un bilan que ce quelle a vécu, sur les montagnes émotionnelles, sur le traitement et ses effets, mais aussi de cette envie de se battre pour faire connaître le cancer triple négatif et pour faire avancer la recherche. Bonne écoute. Le podcast Triple Négatif : instagram.com/triplenegatif/ https://linktr.ee/TripleNegatif Programme COMPASS de Gustave Roussy : https://www.gustaveroussy.fr/fr/octobre-rose-2021-mobilisons-nous-contre-le-cancer-du-sein Pour nous suivre : Emilie Daudin : instagram.com/emiliebrunette/ Emilie Le Guiniec : instagram.com/emiliequarks/ Pow[Her] : instagram.com/powher_officiel Mixé par Charlotte : instagram.com/_charlotteds_ pow-her.fr

PARTAGEZ VOS RECOS PODCASTS sur le répondeur du podcast, juste ici. J'en fais un épisode chaque vendredi.--Je me permets de prendre le micro avant Dimanche et exceptionnellement cette semaine, a l'occasion de la journée international de lutte contre le cancer.Chaque année, le 4 février, l'OMS qui est l'organisation mondiale de la santé, s'associe au centre international de recherche sur le cancer aussi connu sous l'acronyme CIRC afin de promouvoir les moyens de faire reculer la morbidité que l'on doit a cette maladie. Car oui, chaque année, 9.6 millions de personnes décèdent du cancer. C'est plus que le VIH / SIDA, la malaria et la tuberculose réunis. Selon l'OMS, environ 1 tiers de ces décès peut être évité et si détecté suffisamment tôt alors un autre tiers d'entre eux serait même guérissable ! c'est pas complètement dingue ?Vous le savez peut être si vous m'écoutez ailleurs qu'ici, mais les sujets dont on n'ose pas parler sont des sujets qui me passionnent et qui me collent a mon micro. Je ne suis ni médecin ni chercheur, enfin je ne le suis plus, mais je pense que parler peut contribuer à la prévention. Alors aujourd'hui, j'ai eu envie de vous proposer une sélection d'épisodes et de podcasts qui traitent du cancer.Parce que savoir c'est parfois pouvoir.La sélection inclue les podcasts suivants :Combattre le cancer par l'institut pasteur (16 min) https://www.pasteur.fr/en/research-journal/news/fighting-cancer-podcastCombattantes par Marielle Fournier pour RTL Originals (épisode 1, 21 min) https://podcasts.apple.com/fr/podcast/les-combattantes/id1481806786Expat Families par Cindy Cauley (épisode 29, Jenny - Combat contre un cancer du sein pendant sa grossesse en Australie, 80 min) https://expatfamiliespodcast.buzzsprout.com/1118852/7025347-e29-jenny-combat-contre-un-cancer-du-sein-pendant-sa-grossesse-en-australieTriple Négatif par Emilie Daudin (épisode 1, 10 min) https://open.spotify.com/show/3RhmqO6sGxOtzdZ2csfPSNInterception de France Inter (Les enfants de Gustave Roussy, la vie malgré le cancer, 50 min) https://www.franceinter.fr/emissions/interception/interception-11-fevrier-2018Inspire de Mélody (Judith & Juliette - Rien ne se passera comme prévu, mais tu vas y arriver, 52 min)https://open.spotify.com/episode/35IQ3oBkQYvvzCP9azJr06?si=2DG2hGyMQ82j3KkM-uCfewPatients Ensembles de Céline (Franck Marandet, le cancer du sein chez l'homme, 18 min) https://podcast.ausha.co/patients-ensemble/podcast-26-franck-marandet-le-cancer-du-sein-chez-l-hommePour savoir pourquoi, il faut écouter l'épisode ou lire l'article rédigé pour l'occasion juste ici. Et pour retrouver toutes les recommandations, abonne-toi à la playlist Génération Podcast sur Spotify.-------Découvre mes autres podcasts par ici : French Expat Le Podcast, le podcast des voyageurs expats autour du mondeAlors C'est Pour Bientôt, le podcast qui lève le tabou sur les itinéraires bis vers la parentalitéSinon je crée et produis des podcasts pour les autres, et tu peux trouver plus d'infos sur mon site www.annefleurandrle.com Voir Acast.com/privacy pour les informations sur la vie privée et l'opt-out.